Rilonacept for the treatment of recurrent pericarditis

Fava, Agostina M.; Reyaldeen, Reza; Presti, Saberio Lo; Goyal, Amit; Akintoye, Emmanuel; Hughes, Diarmaid; Klein, Allan L.

doi:10.1080/14712598.2022.2005024

Cited by 6 publications

(3 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recombinant IL-1 receptor antagonist anakinra, an inducible receptor rilonacept that binds to IL-1α and IL-1β, and the other one is IL-1β neutralizing antibody canakinumab ( Giancane et al, 2016 ). These biological agents have been widely used to treat inflammation-related diseases, including autoimmune diseases ( Sota et al, 2021 ), recurrent pericarditis ( Fava et al, 2021 ), idiopathic arthritis ( Autmizguine et al, 2015 ), gout ( Perez-Ruiz et al, 2014 ). However, the clinical trials of these biologics in AD are rarely reported.…”

Section: Nlrp3 Inflammasome Inhibitors As a Potential Target For The ...mentioning

confidence: 99%

The Role of NLRP3 Inflammasome in Alzheimer’s Disease and Potential Therapeutic Targets

Liang

Zhang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a common age-related neurodegenerative disease characterized by progressive cognitive dysfunction and behavioral impairment. The typical pathological characteristics of AD are extracellular senile plaques composed of amyloid ß (Aβ) protein, intracellular neurofibrillary tangles formed by the hyperphosphorylation of the microtubule-associated protein tau, and neuron loss. In the past hundred years, although human beings have invested a lot of manpower, material and financial resources, there is no widely recognized drug for the effective prevention and clinical cure of AD in the world so far. Therefore, evaluating and exploring new drug targets for AD treatment is an important topic. At present, researchers have not stopped exploring the pathogenesis of AD, and the views on the pathogenic factors of AD are constantly changing. Multiple evidence have confirmed that chronic neuroinflammation plays a crucial role in the pathogenesis of AD. In the field of neuroinflammation, the nucleotide-binding oligomerization domain-like receptor pyrin domain-containing 3 (NLRP3) inflammasome is a key molecular link in the AD neuroinflammatory pathway. Under the stimulation of Aβ oligomers and tau aggregates, it can lead to the assembly and activation of NLRP3 inflammasome in microglia and astrocytes in the brain, thereby causing caspase-1 activation and the secretion of IL-1β and IL-18, which ultimately triggers the pathophysiological changes and cognitive decline of AD. In this review, we summarize current literatures on the activation of NLRP3 inflammasome and activation-related regulation mechanisms, and discuss its possible roles in the pathogenesis of AD. Moreover, focusing on the NLRP3 inflammasome and combining with the upstream and downstream signaling pathway-related molecules of NLRP3 inflammasome as targets, we review the pharmacologically related targets and various methods to alleviate neuroinflammation by regulating the activation of NLRP3 inflammasome, which provides new ideas for the treatment of AD.

show abstract

Section: Nlrp3 Inflammasome Inhibitors As a Potential Target For The ...mentioning

confidence: 99%

The Role of NLRP3 Inflammasome in Alzheimer’s Disease and Potential Therapeutic Targets

Liang

Zhang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Rilonacept is a dimeric fusion protein with decoy receptors containing extracellular residues of the two IL-1R subunits, IL-1R1 and IL-1R accessory protein (IL-1RAcP), which can bind to and neutralize IL-1β and IL-1α (Jesus and Goldbach-Mansky, 2014). With an improved half-life (7 days) compared to anakinra, rilonacept was approved for the treatment of CAPS in 2008 and was recently approved for recurrent pericarditis in 2021 (Hoffman, 2009;Fava et al, 2022). Canakinumab is an anti-IL-1β monoclonal antibody that selectively binds to and neutralizes IL-1β.…”

Section: Anakinra (Kineret ) Rilonacept (Arcalyst ) and Canakinumab (...mentioning

confidence: 99%

The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases

Blevins

Biby

et al. 2022

Front. Aging Neurosci.

109

View full text Add to dashboard Cite

The NLRP3 inflammasome is a multiprotein complex that plays a pivotal role in regulating the innate immune system and inflammatory signaling. Upon activation by PAMPs and DAMPs, NLRP3 oligomerizes and activates caspase-1 which initiates the processing and release of pro-inflammatory cytokines IL-1β and IL-18. NLRP3 is the most extensively studied inflammasome to date due to its array of activators and aberrant activation in several inflammatory diseases. Studies using small molecules and biologics targeting the NLRP3 inflammasome pathway have shown positive outcomes in treating various disease pathologies by blocking chronic inflammation. In this review, we discuss the recent advances in understanding the NLRP3 mechanism, its role in disease pathology, and provide a broad review of therapeutics discovered to target the NLRP3 pathway and their challenges.

show abstract

“…Finally, rilonacept, a dimeric fusion protein comprised of the extracellular domains of IL‐1R1 and IL‐1RAP, acts as a soluble decoy receptor that quenches IL‐1α and IL‐1β (Figure 1) and blocks inflammation mediated by either or both isoforms. Nonetheless, this ‘IL‐1 trap’ also binds IL‐1Ra, thereby reducing its overall efficacy to inhibit the IL‐1 pathway 8 . Hence, despite the overall success of the currently available IL‐1 blockers, they each have specific limitations, and more effective but safe therapies for IL‐1‐driven diseases are still urgently needed.…”

Section: Figurementioning

confidence: 99%

Turning nature's experiment into a cure

Gander‐Bui

2023

Allergy

View full text Add to dashboard Cite

Rilonacept for the treatment of recurrent pericarditis

Cited by 6 publications

References 43 publications

The Role of NLRP3 Inflammasome in Alzheimer’s Disease and Potential Therapeutic Targets

The Role of NLRP3 Inflammasome in Alzheimer’s Disease and Potential Therapeutic Targets

The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases

Turning nature's experiment into a cure

Contact Info

Product

Resources

About